Date: Thursday, July 18th, 2019
Time: 11 am ET, 8 am PT, 4 pm GMT
Inhibition of the Bile Salt Export Pump (BSEP), which is a membrane transport protein present in the liver, is now considered to be one of several important mechanisms by which drug induced liver injury (DILI) may arise in humans. Recently the International Transporter Consortium (ITC) issued pragmatic recommendations on experimental methods that can be used to assess BSEP inhibition during drug development, and thereby to reduce and manage DILI risk.
Attend our webinar to hear Dr. Gerry Kenna’s presentation, “How And When To Evaluate BSEP Inhibition To Help Reduce Human DILI Risk: ITC Recommendations”. Dr. Kenna will discuss the ITC guidance on assessing BSEP inhibition during the drug development process in order to reduce and manage DILI risk.
- Adapt in vitro liver models for high-throughput drug discovery
- Drug discovery limitations using hepatic models
- Use of high-content imaging in research
Gerry Kenna, Ph.D. FBTS
Pharmaceutical Director, Safer Medicines Trust